SLC10A1 solute carrier family 10 member 1
ENSG00000100652 · protein coding · Open Targets profile
As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It is strictly dependent on the extracellular presence of sodium (PubMed:14660639, PubMed:24867799, PubMed:34060352, PubMed:8132774). It exhibits broad substrate specificity and transports various bile acids, such as taurocholate, cholate, as well as non-bile acid organic compounds, such as estrone sulfate (PubMed:14660639, PubMed:34060352). Works collaboratively with the ileal transporter (NTCP2), the organic solute transporter (OST), and the bile salt export pump (BSEP), to ensure efficacious biological recycling of bile acids during enterohepatic circulation (PubMed:33222321). {ECO:0000269|PubMed:14660639, ECO:0000269|PubMed:24867799, ECO:0000269|PubMed:34060352, ECO:0000269|PubMed:8132774, ECO:0000303|PubMed:33222321}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 1.7541999816894531 (upper bound 2.316499948501587). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 15 registry trials, updated in the last three years, of the most advanced drugs against SLC10A1 (bulevirtide, hepalatide, myrcludex b), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Junqi NiuThe First Hospital of Jilin University · 2 of 2 trials Phase 2+
- Fusheng WangThe fifth medical center of PLA · 1 of 1 trials Phase 2+
- Oyunbileg JanchivNational Cacer Center of Monglia · 1 of 1 trials Phase 2+
- Qin ZhangShanghai Tong Ren Hospital · 1 of 1 trials Phase 2+
- Yanhang GaoThe First Hospital of Jilin University · 1 of 1 trials Phase 2+
Registry trials of bulevirtide, hepalatide, myrcludex b updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 6 of 14 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
1 trials of drugs against SLC10A1 were stopped early
Terminated, withdrawn and suspended interventional trials of bulevirtide, hepalatide, myrcludex b, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 1 most recent of 1.
- withdrawn · 2023-12-08 · Shanghai HEP Pharmaceutical Co., Ltd. · hepalatide“Not approved by CFDA”
Paediatric incentives and obligations for SLC10A1's drugs
For bulevirtide, hepalatide, myrcludex b: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · SLC10A1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002399-PIP01-18-M01 (bulevirtide, Treatment of chronic hepatitis D infection): PM: decision on the application for modification of an agreed PIP, 10 Aug 2022; compliance positive 8 Sept 2023Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002399-PIP01-18-M01, 2026-11-11
- EU orphan designation: yes · EU/3/15/1500 positive 19 Jun 2015: Treatment of hepatitis delta virus infectionRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/15/1500, 2026-11-11
- Authorised in the EU: yes · Hepcludex: authorised since 31 Jul 2020, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Hepcludex, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of bulevirtide, hepalatide, myrcludex bRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: no · No interventional study of bulevirtide, hepalatide, myrcludex b includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 3 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.